You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股CRO板塊反彈 藥明生物漲5% 拜登生物技術行政命令細節落地
格隆匯9月15日丨港A兩地CRO板塊集體反彈。港股藥明生物漲5%,藥明康德漲超3%,金斯瑞漲超2%;A股凱萊英漲超3%,藥明康德、康龍化成、美迪西漲超2%。消息面上,白宮昨晚公佈了關於生物技術行政命令的新細節,美國國家安全顧問傑克·沙利文等參會人員將共同採取措施推進提供超過20億美元的資金,以推進拜登週一提出的啓動國家生物技術和生物製造計劃的行政命令。其中衛生和公共服務部將投資4000萬美元,擴大生物製造在活性藥物成分(API)、抗生素以及生產基本藥物和應對流行病所需的關鍵起始物料方面的作用;國防部(DoD)將在5年內投資10億美元於國內生物產業製造基礎設施。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account